To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel backs Amgen's biosimilar Humira

FDA's Arthritis Advisory Committee voted unanimously Tuesday to recommend approval of ABP 501 from Amgen

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE